|Articles|December 8, 2021
Daily OTC Pearl: Ayr Saline Nasal Gel
Author(s)Saro Arakelians, PharmD
Ayr helps add moisture inside the nose to dissolve and soften thick or crusty mucus.
Advertisement
OTC/Lifestyle Pearl of the Day: Ayr Saline Nasal Gel
Indication: Ayr is used to treat dryness inside the nose (nasal passages).
Insight:
- Ayr helps add moisture inside the nose to dissolve and soften thick or crusty
mucus . - In babies and young children with stuffy noses who cannot blow their noses, using this product helps to make the mucus easier to remove with a nasal bulb syringe. This helps relieve stuffiness and makes breathing easier.
- This product contains a purified gentle salt solution, also called saline or sodium
chloride solution. It does not contain anymedication . - Directions: Spray Ayr into each nostril as needed or as directed by a physician. This product may also be given into the nose as drops or a stream.
- Adverse effects usually do not occur with use of this product. However, if the inside of the nose is very dry and irritated, stinging may occur. If this effect persists or worsens, a physician or
pharmacist should be contacted promptly. - Caution: Do not share this product with others.
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Articles
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025
- Advise Patients About Self-Care Measures to Treat Mild to Moderate GI Issues
September 18th 2025
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
2
Updated IMWG Guidelines Spotlight MRD, Functional Imaging, and Light Chain Assays in Multiple Myeloma
3
IMS 2025: Future Directions for CAR T Therapy in Relapsed and Refractory Multiple Myeloma
4
Elranatamab Plus Daratumumab and Lenalidomide Yields Durable Responses, Manageable Safety
5